PTPRC and myasthenia gravis: Prior to recent evidence suggesting that MG can be reliably identified using MG-specific surface markers [9, 20–23], relative expression of the CD45 surface marker by flow cytometry was among the few available methods to distinguish MG from infiltrating myeloid cells [2–4].